[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Boston Scientific Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":609},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,45,69,106,127,152,174,196,218,242,264,286,307,339,368,390,411,438,456,480,511,530,556,576,595],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642130","impact-of-endoscopic-sleeve-gastroplasty-esg-in-obese-adults-with-type-2-diabetes-t2d-100642130",false,"NCT07639684","Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)","Metabolic Effects of Endoscopic Sleeve Gastroplasty in Obese Adults With Type 2 Diabetes: Evaluation of Glycemic Control, Insulin Use and Obesity Response","MEASURE","Inclusion Criteria:\n\n* Willing and able to provide written informed consent to participate in the study\n* Age ≥ 22 years\n* BMI 30 - 50 kg\u002Fm2\n* HbA1c 7.5 - 10.5%\n* Type 2 Diabetes treated with incretin-based medication (aka GLP-1RA agonist or GLP-1RA\u002FGIP dual agonist) at a stable, maximal tolerated dose for a minimum of 6 months +\u002F- any other oral glucose lowering medications AND intention to initiate insulin therapy for glycemic management\n* Stable weight (\\\u003C 5% TBW) within the 3 months prior to screening\n* Meets the indications for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, excluding the following but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis; varices; or vascular malformation), coagulopathy and antiplatelet\u002Fanticoagulant therapy that cannot be corrected\n* Declines or is ineligible for metabolic bariatric surgery\n* Agrees to abstain from taking any weight loss treatments or supplements that are not part of the lifestyle modification program for a year following the ESG procedure\n* Willing and able to comply with the study procedure with standard of care lifestyle modification program and visit schedule.\n\nExclusion Criteria:\n\n* Diabetes management with insulin. Prior use of insulin for gestational diabetes or short-term use (up to 1 month) in conjunction with an acute condition is acceptable.\n* Noncompliance with medication regime for diabetic management\n* More than one episode of clinically significant reactive or severe hypoglycemia within the prior 1 year. Reactive hypoglycemia is defined as postprandial hypoglycemia meeting Whipple's Triad; severe hypoglycemia is defined as any hypoglycemic episode requiring assistance from another person to administer carbohydrates, glucagon, or other corrective\u002Fresuscitative action\n* History of ketoacidosis or hyperosmolar nonketotic coma within the past 1 year\n* Has a contraindication for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, including but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis, varices, or vascular malformation), coagulopathy and antiplatelet\u002Fanticoagulant therapy that cannot be correct\n* Prior gastric surgery, including but not limited to LSG or RYGP\n* Any known conditions that impact weight loss or glycemic management\n* Chronic systemic steroids or immunosuppressants taken at the time of enrollment or likely required during the study follow-up\n* CKD stage 3+, defined as eGFR \\\u003C 60 mL\u002Fmin\n* Persistent anemia, defined as hemoglobin \\\u003C 10 g\u002FdL\n* Excessive alcohol consumption, defined as meeting or exceeding sex-based heavy drinking limits\n* Use within the last three months prior to screening of over the counter or prescribed weight loss supplements \u002F medications, or intent to use any weight loss medications or supplements during the study duration.\n* The investigator's medical judgment that the subject is not a candidate for the ESG procedure due to findings, including but not limited to psychological and nutritional evaluation results obtained in the prior 12 months.\n* Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding for a year following the ESG procedure.\n* Vulnerable subject.\n* Current or planned participation in another clinical study.","ALL","22 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and inadequately controlled Type 2 Diabetes (T2D) despite guideline-directed therapy, including Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)-based agents.",[28,29],"Type 2 Diabetes Mellitus (T2D)","Obesity (BMI>30)",[31,32],"Endoscopic Sleeve Gastroplasty (ESG)","OverStitch","NOT_YET_RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":22},"2027-04",{"date":41,"type":22},"2029-07",{"name":43,"class":44},"Boston Scientific Corporation","INDUSTRY",{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100595667","endo-sponge-for-treatment-of-anastomotic-or-hartmanns-stump-leakages-in-lower-pelvic-area-100595667","NCT07035431","Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area","A Prospective Multicenter Trial Evaluating the Safety and Effectiveness of Endo-SPONGE for the Treatment of Anastomotic or Hartmann's Stump Leakages in the Lower Pelvic Area","DRAIN Lower","Inclusion Criteria:\n\n* Confirmed grade B anastomotic leak as per the ISGRC (International Study Group of Rectal Cancer) grading system after colorectal surgery.\n* Subject is eligible for endoscopic intervention.\n* Subject has a transmural defect of at least 2 cm in diameter following colorectal surgery in the lower pelvic area.\n* Subject has an anastomotic or Hartmann's stump leak located within an extraperitoneal cavity.\n* Subject has pre-existing diverting ostomy or an ostomy created prior to the first Endo-SPONGE placement.\n* Subject understands the trial requirements and is willing and able to comply with the study procedures, all protocol-required follow up evaluations and provide written informed consent to participate in the study.\n* Investigator decision that EVT is the most suitable treatment of the available treatment options.\n\nExclusion Criteria:\n\n* Subject is under 18 years of age.\n* Potentially vulnerable subject, including, but not limited to pregnant women.\n* Subject has undergone EVT or other similar interventions for the current colorectal indication.\n* Subject had colorectal surgery more than 60 days prior to the planned study procedure.\n* Subject has any necrotic tissue that would require endoscopic debridement prior to Endo-SPONGE placement.\n* Subject has known contraindication for EVT as per the IB.\n* Subject is currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor.","18 Years",{"count":55,"type":22},66,[25],"This study is intended to evaluate the safety and effectiveness of Sponge-based Endoscopic Vacuum Therapy (EVT) using Endo-SPONGE for the treatment of Anastomotic Leaks (AL) or Hartmann's stump leakages following colorectal surgery in a prospective multi-center study.",[59,60],"Anastomotic Leaks","Hartmanns Stump Leakage","RECRUITING",{"date":36,"type":37},{"date":64,"type":22},"2026-09",{"date":66,"type":22},"2028-12",{"name":43,"class":44},10,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100621966","therasphere-japan-pre-market-study-100621966","NCT07377487","TheraSphere Japan Pre-Market Study","A Prospective Single-arm Study of BSJ019T in Japanese Patients With Unresectable Hepatic Malignancy Who Have Failed or Are Not Eligible for Standard Treatment","INDIGO","Inclusion Criteria:\n\n\\[Inclusion criteria based on the clinical evaluation\\]\n\n1. Patient aged \\>18 years at time of consent\n2. Patient is able and willing to participate in the study and has provided written informed consent\n3. Patient who is determined to have failed or not be eligible for standard treatment by the multidisciplinary board\n4. Primary or secondary liver cancer (by histology or imaging)\n5. Measurable disease defined as at least one uni-dimensional measurable liver lesion by CT\u002FMRI (according to RECIST 1.1)\n6. Liver dominant disease (patient prognosis is driven by liver tumor)\n7. Tumor replacement \\\u003C50% of total liver volume based on visual estimation by the investigator\n8. Expected life expectancy ≥ 3 months or more from the index procedure\n9. ECOG Performance Status score of 0 or 1\n10. Negative pregnancy test in women of child-bearing potential\n11. Adequate contraception for the patient and his\u002Fher sexual partner when applicable.\n12. Adequate liver function, as defined by:\n\n    * Child Pugh A or to B7 (HCC)\n    * Must have bilirubin ≤ 2 mg\u002FdL\n    * ALT and AST must be \\\u003C5 x ULN\n    * Albumin ≥3.0 g\u002FdL\n13. Adequate renal function, as defined by:\n\n    • Serum creatinine must be ≤1.5 x ULN\n14. Adequate hematological function, as defined by:\n\n    * Neutrophil count \\> 1200 \u002Fmm3\n    * hemoglobin ≥85 mg\u002FL\n    * platelet count \\>50 x 109\u002FL\n    * INR must be \\\u003C2.0 or \\>50% prothrombin activity\n\n    \\[Inclusion Criteria based on the imaging evaluation\\]\n15. After 99mTc MAA administration, in SPECT\u002FCT imaging, good PVT targeting and uptake of 99mTc MAA, if present\n16. Future liver remnant volume (FLRV) \\>30% of whole liver volume. FRLV is the volume of liver not planned to be treated with TheraSphere and free of tumor\n\nExclusion Criteria:\n\n\\[Exclusion Criteria based on the clinical evaluation\\]\n\n1. Vp4 according to the Liver Cancer Study Group of Japan (LCSGJ) portal vein tumor thrombosis classification1\n2. History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically.\n3. Contraindications to angiography and selective visceral catheterization\n4. Received any prior external beam radiation treatment to the liver\n5. Received any prior yttrium-90 microsphere treatment to the liver\n6. Received previous peptide receptor radionuclide therapy (PRRT)\n7. Plan to start systemic anticancer treatment in the next 3 month after the index procedure.\n8. Presence of ongoing adverse event due to prior therapy as judged by the principal investigator or sub-investigator to affect the safety evaluation of the study device.\n9. Evidence of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease\n10. Undergone any intervention for, or compromise of, the Ampulla of Vater within that last 3 months or patient with biliodigestive anastomosis.\n11. Presence of ascites, clinical or radiological, \"trace\" of ascites is acceptable.\n12. Presence of Hepatic encephalopathy (Grade ≥2)\n13. Previous liver function decompensation within the last 6 months (ascites, encephalopathy, jaundice)\n14. Patient with infiltrative disease presentation (not suitable for repeated measurement)\n15. Patients who are pregnant or breast-feeding and does not want to stop.\n16. Have any disease or condition that would preclude the safe use of BSJ019T, including concurrent dialysis treatment, or unresolved serious infections\n17. Participating in concurrent clinical studies or interventional clinical studies\n18. Any condition where the Investigator feels the patient would not be able to participate\u002Ffinish the study\n19. Previous gastrointestinal bleeding related to portal hypertension within the last 3 months (preventive treatment is acceptable)\n\n    \\[Exclusion Criteria based on the imaging evaluation\\]\n20. Dose to the lung \\> 30Gy for a single treatment or cumulative \\>50 Gy\n21. Evidence of any off-target extrahepatic and liver deposition on 99mTc-MAA that cannot be corrected using angiographic techniques\n22. Cone Beam CT (CBCT) or 99mTc-MAA hepatic arterial perfusion scintigraphy shows poor tumor perfusion and\u002For poor tumor targeting that would lead to a dose that does not meet the liver dosing criteria as specify in the protocol",{"count":78,"type":22},51,[25],"To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.",[82],"Liver Neoplasms",[84,85,86,87,88,89,90,91,92,93,94,95,96,97],"Carcinoma","Carcinoma, Hepatocellular","Neoplasms","Digestive System Neoplasms","Neoplasms, Glandular and Epithelial","Neoplasms by Histologic Type","Neoplasms by Site","Digestive System Diseases","Liver Diseases","Neoplasm Metastasis","Colorectal Neoplasms","Colonic Diseases","Carcinoma, Neuroendocrine","Neuroendocrine Tumors","2026-08-18",{"date":34,"type":37},{"date":101,"type":37},"2026-01-22",{"date":103,"type":22},"2027-12-31",{"name":43,"class":44},4,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":126},"100620137","a-study-on-the-acquisition-of-2d-ice-images-with-the-chorus-idx-system-in-subjects-undergoing-an-ablation-procedure-100620137","NCT07353710","A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure","SONAR-ICE","Inclusion Criteria:\n\n1. Subjects who are able and willing to provide written informed consent prior to any study procedure.\n2. Subjects who are planned for an ablation procedure for any atrial arrhythmia using any commercially available Boston Scientific Ablation System, per physician's judgement and hospitals' standard practice.\n3. Subjects who are willing and able to participate in all testing and assessments associated with this clinical study at an approved clinical investigation center.\n4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Any of the following cardiac implanted devices\n\n   * Any prosthetic mitral or tricuspid heart valve, such as ring, repairs or clips\n   * Atrial septal defect (ASD) occluders including interatrial baffle, closure device, patch, or patent foramen ovale or ASD occluder\n2. Subjects with contraindications related to the use of the CHORUS IDx™ System:\n\n   * Subjects with inadequate vascular access\n   * Subjects with active systemic infection\n   * Subjects with presence of a known intracardiac thrombus in the chamber of use\n3. Women who are confirmed to be pregnant or lactating at the time of the Index Procedure\n4. Presence of other medical conditions, that, in the investigator's opinion, could limit the subject's ability to participate in the study\n5. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility",{"count":114,"type":22},200,[25],"A first-in-human prospective data collection study including subjects who are planned to undergo an ablation procedure for any atrial arrhythmia as per medical judgement and the site's standard practice, represents the most viable means to collect human anatomy ICE images for the purpose of software development.",[118,119],"Atrial Arrhythmia","Intracardiac Echocardiography",{"date":121,"type":37},"2026-08-19",{"date":123,"type":37},"2026-07-28",{"date":103,"type":22},{"name":43,"class":44},8,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},"100594129","randomized-study-on-transoral-outlet-reduction-and-lifestyle-changes-for-weight-regain-after-gastric-bypass-100594129","NCT07015424","Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass","Prospective, Randomized Clinical Study Evaluating Transoral Outlet Reduction (TORe) and Lifestyle Modification for Patients With Weight Regain Following Roux-en-Y Gastric Bypass","REIGNITE","Inclusion Criteria:\n\n* 18 years or older.\n* Experiencing weight regain (≥ 20% weight from nadir) after achieving clinically successful weight loss.\n* Willing to have a TORe procedure for the treatment of weight regain.\n* BMI between 30 and 50 kg\u002Fm2, inclusive.\n* GJA diameter ≥ 20 mm, confirmed either during a\n* Screening EGD completed ≤ 60 days from study procedure or\n* EGD performed immediately prior to the TORe procedure.\n* Anatomically accepting of the procedure, including a pouch size that will not require reduction at the time of treatment (pouch that is shorter than 6 cm in length).\n* Agrees not to take additional over the counter or prescribed weight loss supplements \u002F medications (including incretins) during the first 6 months of the study.\n* Is on a stable dose of anti-diabetic medication for three months with no anticipated changes during the first 6 months of the study.\n* Agrees to the follow-up requirements of the study and is able to read, understand, and sign a written Informed Consent Form to participate in the study.\n* Meets the indications for TORe procedure with OverStitch™ Endoscopic Suturing System.\n\nExclusion Criteria:\n\n* Current use or use within the three months prior to the baseline visit of over the counter or prescribed weight loss supplements \u002F medications (including incretins).\n* Current or planned management of Type 2 Diabetes with incretin medications.\n* Inability or unwillingness to comply with assigned treatment or protocol requirements related to visits.\n* Investigator's medical judgement that the subject is not a candidate for the TORe procedure.\n* Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding in the next two years.\n* Vulnerable subject.",{"count":136,"type":22},108,[25],"The goal of this clinical trial is to evaluate weight loss with TORe and intensive lifestyle modification versus intensive lifestyle modification alone in subjects who have regained weight following a Roux-en-Y gastric bypass.\n\nParticipants will randomized 2:1. Those randomized to the TORe arm will receive a TORe procedure and intensive lifestyle modification which consists of a well-balanced calorie restrictive diet, incorporation of exercise and coaching on lifestyle discussion. Participants randomized the lifestyle modification alone arm will be eligible to receive a TORe procedure at 6 months post enrollment. Total follow up will be 24 months.",[140,141],"Weight Regain","Weight Loss",[143,32],"TORe","2026-08-17",{"date":121,"type":37},{"date":147,"type":37},"2026-04-14",{"date":149,"type":22},"2028-11",{"name":43,"class":44},9,{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":160,"targetDuration":162,"studyType":163,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100414311","drug-eluting-registry-real-world-treatment-of-lesions-in-the-peripheral-vasculature-100414311","NCT04674969","Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature","Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature (ELEGANCE)","ELEGANCE","Inclusion Criteria:\n\n* Patients 18 years and older\n* Written informed consent (patient data release-form)\n* Use of any commercially available Boston Scientific drug-eluting device marketed for treatment of lesions in the peripheral vasculature and specified in the Registry Enrollment Guide\n\nExclusion Criteria:\n\n* Life expectancy of \\\u003C1 year",{"count":161,"type":22},5000,"5 Years","OBSERVATIONAL","The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.",[166],"Peripheral Vascular Diseases",{"date":121,"type":37},{"date":169,"type":37},"2021-03-29",{"date":171,"type":22},"2028-01",{"name":43,"class":44},82,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100601167","pvi-alone-vs-pvi-and-linear-ablation-for-persistent-atrial-fibrillation-prompt-af-ii-100601167","NCT07106970","PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)","Linear Ablation Added to Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Pulsed Field Ablation for Persistent Atrial Fibrillation: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\nStudy subjects are required to meet all the following inclusion criteria:\n\n1. Subjects with an age range of 18 years or above and 80 years or below.\n2. Subjects have symptomatic, drug-resistant, persistent AF, defined as:\n\n   1. Symptomatic: these symptoms include but not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath.\n   2. Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one AAD.\n   3. Persistent: continuous AF for \\> 90 days, i) with a minimum a physician's note confirming the diagnosis AND,within 180 days of Enrollment Date, either a 24-hour or longer continuous ECG recording confirming continuous AF OR Two ECGs showing continuous AF taken at least 90 days apart.\n3. Subjects undergoing a first-time ablation procedure for AF.\n4. Subjects who are willing and capable of providing ICF and participating in all testing associated with this study.\n\nExclusion Criteria:\n\n1. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible\u002Fnon-cardiac causes.\n2. Left atrial anteroposterior diameter ≥ 6.0 cm by transthoracic echocardiography (TTE) within 3 months prior the procedure.\n3. Heart failure with left ventricular ejection fraction (LVEF) \\\u003C 30% by TTE within 3 months prior the procedure.\n4. LA thrombus detected by Transesophageal Echocardiography (TEE) or cardiac CT within one day before the procedure or Intracardiac Echocardiography (ICE) before atrial septal puncture during the procedure.\n5. Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, mechanical valve, interatrial baffle, closure device, patch, or patent foramen oval occlude, left atrial appendage closure at the time of ablation.\n6. Any of the following events within 90 days of the Consent Date:\n\n   1. Myocardial infarction, unstable angina or coronary intervention or any cardiac surgery\n   2. Pericarditis or symptomatic pericardial effusion\n   3. Gastrointestinal bleeding\n   4. Stroke, transient ischemic attack (TIA), or intracranial bleeding or any non-neurologic thromboembolic event\n7. Contraindication to, or unwillingness to use systemic anticoagulation.\n8. Subjects cannot be removed from Class I\u002FIII AAD for reasons other than atrial arrhythmia.\n9. Women of childbearing potential who are pregnant or lactating.\n10. Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL\u002Fmin\u002F1.73 m2, or with any history of renal dialysis or renal transplant.\n11. Conditions that in the investigator's medical opinion would interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.\n12. Predicted life expectancy less than 12 months.","80 Years",{"count":183,"type":22},640,[25],"This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)",[187],"Persistent Atrial Fibrillation","2026-08-14",{"date":144,"type":37},{"date":191,"type":37},"2025-08-28",{"date":193,"type":22},"2028-08-30",{"name":43,"class":44},1,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":204,"targetDuration":206,"studyType":163,"phases":4,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":195},"100579097","a-real-world-study-of-ekosonic-endovascular-system-in-chinese-populations-with-acute-pulmonary-embolism-100579097","NCT06819865","A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism","EkoSonic Endovascular System in China RWS(ANTEATER)","ANTEATER","Inclusion Criteria:\n\n1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \\\u003C 14 days).\n2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image\n3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.\n\nExclusion Criteria:\n\n1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \\\u003C 14 days).\n2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image\n3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.",{"count":205,"type":22},30,"6 Months","This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.",[209],"Acute Pulmonary Embolism",[211],"PE",{"date":144,"type":37},{"date":214,"type":22},"2026-08-30",{"date":216,"type":22},"2029-05-30",{"name":43,"class":44},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":224,"targetDuration":226,"studyType":163,"phases":4,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100613105","watchman-flx-pro-european-registry-100613105","NCT07262255","WATCHMAN FLX Pro European Registry","Inclusion Criteria:\n\n1. Subject is attempted to be treated with the WATCHMAN FLX™ Pro LAAC device.\n2. Subject has non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve) and is clinically indicated for a WATCHMAN FLX™ Pro LAAC device, per the Instructions for Use (IFU).\n3. Subject or legal representative who are willing and capable of providing informed consent.\n4. Subject is able and willing to return for required follow-up visits and examinations.\n5. Subject whose age is 18 years or above, or who is of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subject has a documented life expectancy of less than 12 months.\n2. Subject who is currently enrolled in another investigational study or registry except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments.\n3. Intracardiac thrombus is present.\n4. An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.\n5. The LAA anatomy will not accommodate a Closure Device.\n6. Subject has a known hypersensitivity or contraindications according to IFU.\n7. Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study.",{"count":225,"type":22},1000,"12 Months","The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.",[229,230],"Non-valvular Atrial Fibrillation (AF)","Left Atrial Appendage Closure",[232],"LAAC","2026-08-12",{"date":235,"type":37},"2026-08-13",{"date":237,"type":37},"2025-12-17",{"date":239,"type":22},"2028-09",{"name":43,"class":44},19,{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":250,"targetDuration":251,"studyType":163,"phases":4,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":105},"100597715","safety-and-effectiveness-of-orbera365-intragastric-balloon-system-100597715","NCT07062094","Safety and Effectiveness of Orbera365™ Intragastric Balloon System","Safety and Effectiveness of Orbera365™ Intragastric Balloon System: A Multi-Center, Prospective, Standard of Care Registry","Orbera365","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age\n2. Subject meets the indicated population for the device according to the Instructions for Use (IFU) including obese patients with the BMI of 30-50 kg\u002Fm2 for weight loss and patients with BMI 40 kg\u002Fm2 and above or a BMI of 35 kg\u002Fm2 with comorbidities before obesity or another surgery, unless contraindicated.\n3. Subject is able to read, understand, and sign a written Informed Consent Form to participate in the registry\n\nExclusion Criteria:\n\n1. Subject is planning on becoming pregnant during the one year following study device placement\n2. Subject will complete follow-up visits at a location that the treating physician does not practice\n3. Subjects who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.\n4. Current use or use within the three months before the baseline visit of over-the-counter or prescribed weight loss supplements\u002Fmedications.\n5. Subjects who have conditions that are contraindicated for Orbera365™ IGB System as per the IFU, including, but not limited to:\n\n   * The presence of more than one IGB at the same time.\n   * Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n   * Potential upper gastrointestinal bleeding conditions\n   * A large hiatal hernia of \\> 5cm or a hernia ≤ 5 cm associated with severe or intractable gastro- esophageal reflux symptoms\n   * A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and\u002For an endoscope\n   * Achalasia, symptoms suggestive of delayed gastric emptying, or presence of any other severe motility disorder that that may pose a safety risk during placement or removal of the device.\n   * Gastric Mass.\n   * Severe coagulopathy.\n   * Taking aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants and not under medical supervision.\n   * Prior surgery involving the esophagus, stomach, and duodenum or bariatric surgery",{"count":114,"type":22},"13 Months","This is a prospective, multi-center, standard of care registry offered to subjects in the EU only that have already agreed to receive the Orbera365™ Intragastric Balloon (IGB) System for weight loss. Subjects that agree to participate in the registry will have data reported associated with standard of care weight management visits during the time the device is implanted (in-dwell period), with an additional visit 30 days after the removal procedure.",[254],"Obesity",[248,256,254,257],"Intragastric Balloon","Orbera365™ IGB System",{"date":235,"type":37},{"date":260,"type":37},"2026-04-07",{"date":262,"type":22},"2028-05-01",{"name":43,"class":44},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":195},"100634268","respiration-measured-via-end-tidal-co2-and-spirometry-study-respi-100634268","NCT07537478","Respiration Measured Via End-tidal CO2 and Spirometry Study (RESPI)","Respiration Measured Via End-tidal CO2 and Spirometry Study","RESPI","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Age 18 or above\n* Full time or part time BSC employee\n* Willing and able to participate in the required testing\n\nExclusion Criteria:\n\n* Currently enrolled in another clinical trial that might interfere with data collection or placement of the study system\n* Subject is pregnant as indicated by subject report\n* Known allergy or sensitivity to materials used in the study (Neoprene, Nylon)\n* Any past or current medical event that could represent a risk for the subject to perform the study required activities in the opinion of the investigator",{"count":21,"type":22},"To collect respiration data via end-tidal CO2 and spirometry and compare respiration rates measured via the two methods.",[275],"Respiration Rate Detection",[277,278],"end tidal co2","spirometry","2026-08-11",{"date":233,"type":37},{"date":282,"type":37},"2026-05-28",{"date":284,"type":22},"2026-08",{"name":43,"class":44},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":295,"conditions":296,"keywords":299,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":306,"locationsCount":195},"100631585","fainting-detection-and-early-warning-in-syncope-evaluation-study-arise-100631585","NCT07502599","Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)","Fainting Detection And Early Warning In Syncope Evaluation Study","ARISE","Inclusion Criteria:\n\n* Willing and capable to provide informed consent\n* Age 18 or above\n* Previously underwent a clinically indicated ARS assessment without complications (including deep breathing, Valsalva maneuver, and tilt table testing).\n* Previously diagnosed with OH, Vasovagal syncope, OR control subjects assessed as normal, based on the ARS assessment. Participant enrollment shall be based on the type of diagnosis.\n* Willing to complete all required study activities.\n\nExclusion Criteria:\n\n* Currently enrolled in another clinical trial that might interfere with data collection.\n* Subject is pregnant or planning to become pregnant during the study\n* Active Implantable Medical Device, e.g. cardiac implantable electronic devices, bladder stimulators, diaphragm stimulators, implantable neuro stimulator, implantable active monitoring devices, implantable active drug administration devices, etc.\n* Have a prosthetic cardiac valve or previously underwent cardiac valve surgery.\n* Known allergy to materials used in the study (adhesive, ECG electrodes)\n* Diagnosed with syncope due to cardiologic causes.\n* Have had a myocardial infarction in the previous 90 days\n* Have been diagnosed with tachycardia that requires current medical treatment\n* Have any contraindications for exercise testing, tilt table test, Valsalva maneuver test or deep breathing test (judged by the study Principal Investigator)",{"count":5,"type":22},"To characterize the impact of orthostatic hypotension (OH) and Vasovagal syncope on signals measured using a wearable Holter monitor in the clinic and ambulatory setting.\n\nTo evaluate the relationship of signals measured from the Holter monitor with reported symptom severity of orthostatic intolerance per standard data collection, analysis, and questionnaires.",[297,298],"Orthostatic Hypotension","Reflex Syncope",[300,301],"tilt table test","valsalva",{"date":233,"type":37},{"date":304,"type":37},"2026-08-06",{"date":239,"type":22},{"name":43,"class":44},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":315,"targetDuration":317,"studyType":163,"phases":4,"briefSummary":318,"conditions":319,"keywords":324,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":338},"100609076","safety-performance-and-clinical-benefit-of-pacing-the-left-bundle-branch-area---post-market-clinical-follow-up-100609076","NCT07209852","Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up","Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up (SEPTA PMCF)","SEPTA PMCF","Inclusion Criteria:\n\n1. Subjects intended to undergo initial (de novo) pacing system implant using the INGEVITY+ lead in the left bundle branch area (LBBA) and a Boston Scientific single or dual- chamber pacemaker (Note: no prior attempted pacing system components);\n2. Subjects who are indicated for and will receive a Boston Scientific pacemaker system (including the single or dual chamber pacemaker and an INGEVITY+ lead in the LBBA location) for one of the following medical conditions:\n\n   1. Symptomatic paroxysmal or permanent second- or third-degree AV block,\n   2. Symptomatic bilateral bundle branch block,\n   3. Symptomatic paroxysmal or transient sinus node dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia, sinus arrest, sinoatrial \\[SA\\] block),\n   4. Bradycardia-tachycardia syndrome, to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias,\n   5. Neurovascular (vasovagal) syndromes or hypersensitive carotid sinus syndromes,\n   6. Adaptive-rate pacing for patients exhibiting chronotropic incompetence and who may benefit from increased pacing rates concurrent with increases in minute ventilation and\u002For level of physical activity.\n\n      Dual-chamber and atrial tracking modes are also indicated for patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of the following:\n   7. Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block,\n   8. VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm,\n   9. Low cardiac output or congestive heart failure secondary to bradycardia;\n3. Subjects willing and capable of providing informed consent and participating in all testing and clinic visits associated with the clinical study at an approved clinical study location and at the intervals defined by protocol;\n4. Subjects who are ≥18 years of age, and of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subjects meeting guideline indications for cardiac resynchronization therapy (CRT) in the absence of a bradycardia indication;\n2. Subjects with a known or suspected sensitivity to dexamethasone acetate (DXA);\n3. Subjects with a Mechanical Tricuspid Valve;\n4. Subjects requiring hemodialysis or peritoneal dialysis;\n5. Subject has or has had implanted any pacemaker, ICD system, including subcutaneous, transvenous or leadless systems (Note: except for temporary pacing wire at time of enrollment) or CRT system;\n6. Subjects currently on an active organ transplant list;\n7. Subject referred to or admitted for hospice care;\n8. Subjects with a documented life expectancy of less than 12 months;\n9. Subjects enrolled in any other concurrent study (unless prior approval is received from the Sponsor);\n10. Subjects who are, or plan to become pregnant during the course of the study or are breastfeeding at time of enrollment;\n11. Subjects who are unable or unwilling to comply with the follow-up schedule, including those living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome.",{"count":316,"type":22},140,"3 Years","The goal of this observational post-market clinical Follow-up study is to learn about the long-term safety, performance, and clinical benefits of pacing the left bundle branch area (LBBAP) using the INGEVITY+ pacemaker lead in patients with bradycardia who need a pacemaker.",[320,321,322,323],"Bradycardia","Atrioventricular Block","Sinus Node Dysfunction","Bundle-Branch Block",[325,326,327,328,329,330,331],"Left Bundle Branch Area Pacing (LBBAP)","INGEVITY+ Lead","Pacemaker","Cardiac Pacing","Conduction System Pacing","Ventricular Synchrony","Post-Market Clinical Follow-up",{"date":233,"type":37},{"date":334,"type":37},"2025-12-19",{"date":336,"type":22},"2029-08-31",{"name":43,"class":44},13,{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":358,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},"100607611","managing-pain-using-optimized-sequences-by-adjusting-parameters-with-independent-current-control-100607611","NCT07190807","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control (MOSAIC Study)","MOSAIC","Key Inclusion Criteria:\n\n* Persistent spinal pain syndrome (PSPS) Type I (or non-surgical refractory back pain), or PSPS Type II (Failed Back Surgery Syndrome, FBSS) diagnosis.\n* Diagnosed with chronic pain of the trunk and\u002For limbs for at least 6 months.\n* 18 years of age or older when written informed consent is obtained\n* Able to independently read and complete all questionnaires and assessments provided in English.\n* Signed a valid, IRB or EC approved informed consent form (ICF) provided in English.\n\nKey Exclusion Criteria:\n\n* Any pain-related diagnosis, medical or psychological condition that, in the Investigator's judgment might confound reporting of study outcomes (e.g., vascular or neurogenic claudication, osteoarthritis, plantar fasciitis, pelvic pain, anginal pain, chronic migraine, acute herniated disc, malignancy, untreated major depression, injury claim).\n* Significant cognitive impairment at Screening and Baseline visit that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study\n* A female who is pregnant, lactating, or is of childbearing potential and planning to get pregnant during the study or not using adequate contraception.\n* Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study.",{"count":348,"type":22},70,[25],"Study to evaluate the effectiveness of time variant pulse (TVP)-SCS in patients with chronic pain using commercially approved Boston Scientific SCS Systems per local Instructions for use (IFU).\n\nIn addition, to compile real-world clinical outcomes in subjects with chronic, intractable low back and\u002For leg pain.",[352,353,354,355,356,357],"Chronic Pain","Intractable Pain","Low Back Pain","Chronic Low-back Pain","Chronic Leg Pain","Leg Pain",[359],"Spinal Cord Stimulation","2026-08-10",{"date":279,"type":37},{"date":363,"type":37},"2025-11-07",{"date":365,"type":22},"2029-05",{"name":43,"class":44},7,{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":375,"targetDuration":377,"studyType":163,"phases":4,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":241},"100579666","intracept-minimally-invasive-procedure-for-vertebrogenic-back-pain-100579666","NCT06827262","Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain","IMPROVE","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).\n* Signed a valid, IRB\u002FEC-approved informed consent form.\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Instructions for Use (IFU).",{"count":376,"type":22},1500,"60 Months","Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.",[355,380],"Vertebrogenic Pain Syndrome",[382,383,354],"Intraosseous basivertebral nerve ablation","Axial low back pain",{"date":279,"type":37},{"date":386,"type":37},"2025-03-26",{"date":388,"type":22},"2034-07",{"name":43,"class":44},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":396,"targetDuration":317,"studyType":163,"phases":4,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":410},"100214628","registry-of-deep-brain-stimulation-with-the-vercise-system-vercise-dbs-registry-100214628","NCT02071134","Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry","Key Inclusion Criteria:\n\n* Meets criteria established in locally applicable Vercise System Direction for Use\n* At least 18 years old\n\nKey Exclusion Criteria:\n\n* Meets any contraindication in the Vercise System locally applicable Directions for Use\n\nSubjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.",{"count":376,"type":22},"The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.\n\nThe utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.\n\nAdditionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.",[399],"Parkinson's Disease",[401,402,403],"Deep brain stimulation","Parkinson's disease","Vercise",{"date":279,"type":37},{"date":406,"type":37},"2014-03-04",{"date":408,"type":22},"2038-12",{"name":43,"class":44},85,{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":437},"100187705","relief---a-global-prospective-observational-post-market-study-to-evaluate-long-term-effectiveness-of-neurostimulation-therapy-for-pain-100187705","NCT01719055","RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain","A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain","RELIEF","Key Inclusion Criteria:\n\n* Study candidate is scheduled to be trialed, on-label, with a commercially approved Boston Scientific neurostimulation system for pain, per local directions for use\n* Signed a valid, IRB\u002FEC-approved informed consent form\n* 18 years of age or older\n\nKey Exclusion Criteria:\n\n* Contraindicated for Boston Scientific neurostimulation system\n* Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments",{"count":420,"type":22},4800,"To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Instructions for Use\n\n\\- and -\n\nTo evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice",[423],"Pain",[425,426,427,428,429,430],"stimulation","implantable","pulse generator","back pain","chronic pain","leg pain",{"date":279,"type":37},{"date":433,"type":37},"2012-11-19",{"date":435,"type":22},"2035-05",{"name":43,"class":44},118,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":455},"100174888","patient-retrospective-outcomes-pro-100174888","NCT01550575","Patient Retrospective Outcomes (PRO)","PRO","Key Inclusion Criteria:\n\n* Previously treated with or eligible for use with Boston Scientific Systems\n* 18 years of age or older at the start of Baseline",{"count":446,"type":22},15000,"This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.",[352],{"date":279,"type":37},{"date":451,"type":37},"2012-04-03",{"date":453,"type":22},"2030-12",{"name":43,"class":44},144,{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":470,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":479},"100639755","evaluation-of-the-faraflex-mapping-and-pulsed-field-ablation-system-in-subjects-with-atrial-fibrillation-100639755","NCT07575269","Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation","Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation - A Global Prospective Single Arm Study","FARADIGM","Inclusion Criteria:\n\n1. At least 18 years old (or older if required by local law)\n2. Symptomatic, documented, drug-refractory paroxysmal or persistent atrial fibrillation (AF).\n3. Willing and capable of providing written informed consent\n4. Willing and able to comply with all follow-up assessments and study procedures at an approved investigational site\n\nExclusion Criteria:\n\n1. Any of the following atrial conditions:\n\n   1. Left atrial anteroposterior diameter of at least 5.5 cm, or if not available, non-indexed volume greater than 100 mL\n   2. Any prior atrial endocardial, epicardial, or surgical ablation for atrial arrhythmia (excluding right-sided Supraventricular Tachycardia (SVT) or Cavo-Tricuspid Isthmus (CTI)-dependent flutter)\n   3. Any prior atrial surgery\n   4. Current atrial myxoma\n   5. Pulmonary vein abnormality, stenosis, or prior stenting (common and middle pulmonary veins allowed)\n   6. Current left atrial thrombus\n2. Any of the following cardiovascular conditions:\n\n   1. History of sustained ventricular tachycardia or ventricular fibrillation\n   2. Atrial fibrillation secondary to reversible or non-cardiac causes (e.g., electrolyte imbalance, thyroid disease, alcohol)\n   3. Presence of any of the following cardiac devices or implants:\n\n      * Current or anticipated pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy device\n      * Current implantable loop recorder other than LUX-Dx\n      * Prior interatrial baffle or septal closure device\u002Fpatch (Patent Foramen Ovale (PFO)or Atrial Septal Defect (ASD))\n      * Left atrial appendage closure or occlusion device\n   4. Clinically significant valvular disease, including:\n\n      * Any cardiac valve prosthesis, ring, repair, or clip\n      * Moderate to severe mitral stenosis\n      * Moderate to severe aortic stenosis\n      * Severe mitral regurgitation\n      * Severe tricuspid regurgitation\n   5. Hypertrophic or amyloid cardiomyopathy\n   6. Presence of Inferior Vena Cava (IVC) filter, inability to obtain vascular access, or contraindication to femoral access\n   7. Awaiting cardiac transplantation or other cardiac surgery within 12 months (left atrial appendage closure\u002Focclusion procedures allowed no less than (≥) 60 days after index procedure)\n   8. Severe right ventricular dysfunction per investigator assessment\n3. Any of the following congenital conditions:\n\n   1. Congenital heart disease with clinically significant residual anatomic or conduction abnormalities, or channelopathies\n   2. Known congenital methemoglobinemia\n   3. Known G6PD deficiency\n4. Any of the following medical history conditions:\n\n   1. Solid organ or hematologic transplant, or under evaluation for transplant\n   2. History or current evidence of hemi-diaphragmatic paralysis or paresis\n   3. Prinzmetal angina or severe non-revascularizable coronary disease\n   4. Known coagulopathy or bleeding disorder\n   5. Renal insufficiency, history of dialysis, or renal transplant\n   6. Known allergic reaction to nitroglycerin (excluding hypotension)\n   7. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure\n   8. Active spinal cord stimulator\n5. Any of the following baseline conditions:\n\n   1. NYHA Class III or IV heart failure\n   2. Left ventricular ejection fraction (LVEF) less than 40% within 12 months\n   3. CHA2DS2-VASc score greater than or equal to 5\n   4. Body mass index (BMI) greater than 45.0\n   5. Contraindication to or unwillingness to use systemic anticoagulation peri-procedurally\n   6. Pregnant or lactating at time of procedure\n   7. Severe lung disease, pulmonary hypertension, or oxygen-dependent lung disease\n   8. Active malignancy (excluding squamous cell carcinoma)\n   9. Clinically significant gastrointestinal disease (e.g., severe or erosive esophagitis, uncontrolled reflux, gastroparesis, esophageal candidiasis, active gastroduodenal ulceration)\n   10. Known Active systemic infection\n   11. Life expectancy of less than 1 year\n   12. Concurrent enrollment in another investigational study or registry that may interfere with this study (exceptions include mandatory governmental registries or purely observational registries with sponsor approval)\n6. Any of the following events within 90 days prior to consent:\n\n   1. Myocardial infarction, unstable angina, or coronary intervention\n   2. Pericarditis or symptomatic pericardial effusion\n   3. Gastrointestinal bleeding\n   4. Cardiac surgery\n   5. Stroke, Transient Ischemic Attack (TIA), or intracranial bleeding\n   6. Any active non-neurologic thrombus and\u002For thromboembolic event\n   7. Carotid stenting or endarterectomy\n   8. Heart failure hospitalization\n   9. Uncontrolled diabetes mellitus or HbA1c greater than 8.0%\n7. Other conditions:\n\n   1. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted ICM from the LUX-Dx family of devices\n   2. Any medical condition that, in the investigator's opinion, would interfere with study participation, increase risk, or affect data interpretation",{"count":465,"type":22},571,[25],"The goal of this clinical trial is to learn if the FARAFLEX™ Mapping and pulsed field ablation (PFA) System can safely and effectively treat symptomatic, drug-refractory Paroxysmal atrial fibrillation (PAF) and Persistent atrial fibrillation (PersAF). The main question it aims to answer is:\n\nIs the FARAFLEX Mapping and PFA System a safe and effective treatment for patients?\n\nParticipants will undergo an ablation procedure using the FARAFLEX Mapping and PFA System.",[469,187],"Paroxysmal Atrial Fibrillation (PAF)",[471],"pulsed field ablation","2026-08-04",{"date":304,"type":37},{"date":475,"type":37},"2026-07-07",{"date":477,"type":22},"2030-01-01",{"name":43,"class":44},6,{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":498,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":510},"100619784","option-emea-clinical-trial-100619784","NCT07349121","OPTION-EMEA Clinical Trial","Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation - Europe, Middle East and Africa [OPTION-EMEA]","OPTION-EMEA","Inclusion Criteria:\n\n1. Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN FLX™ Pro or WATCHMAN FLX™ for LAAC, per physician medical judgement and as per hospitals' standard of care.\n2. Subjects who are willing and able to provide informed consent.\n3. Subjects who are willing and able to participate in all testing associated with this clinical study at an approved investigational center.\n4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subjects who underwent prior AF ablation procedure.\n2. Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes.\n3. Already surgically closed or otherwise excluded LAA.\n4. The LAA anatomy does not accommodate a Closure Device.\n5. Known or suspected atrial myxoma.\n6. Presence of intracardiac thrombus\\*.\n7. Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an atrial septal defect (ASD) \u002F patent foramen ovale (PFO) device.\n8. Subjects with a presence of a mechanical valve prosthesis in any position.\n9. Subjects with a myocardial infarction within 90 days prior to enrollment.\n10. Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within 90 days prior to enrollment.\n11. Any planned electrical cardioversion within 30 days following LAAC device implant.\n12. Subjects with a known inability to obtain vascular access.\n13. Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present.\n14. Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina).\n15. Subjects with any contraindications to short term use of anticoagulation therapy for conditions different from atrial fibrillation.\n16. Subjects who are pregnant or planning to be pregnant.\n17. Subjects with a life expectancy of ≤ 1 year per investigator's opinion.\n18. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.",{"count":489,"type":22},500,[25],"The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case.\n\nThe study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.",[493,494,230,495,496,497],"Atrial Fibrillation (AF)","Stroke Prevention in Patients With Atrial Fibrillation","Pulsed Field Ablation","Atrial Fibrillation Ablation Procedure","Concomitant Procedures",[499,500,501,502,232],"WATCHMAN","FARAPULSE","Concomitant","PFA",{"date":504,"type":37},"2026-08-05",{"date":506,"type":37},"2026-06-18",{"date":508,"type":22},"2029-12",{"name":43,"class":44},5,{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":518,"maxAge":4,"enrollmentInfo":519,"targetDuration":317,"studyType":163,"phases":4,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":529},"100261711","vercise-dbs-dystonia-prospective-study-100261711","NCT02686125","Vercise™ DBS Dystonia Prospective Study","Prospective Study of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia","Inclusion Criteria (IC):\n\n* IC1. Meets criteria established in the locally applicable Vercise System Directions for Use (DFU) for dystonia.\n* IC2. At least 7 years old. Parent or guardian consent is required in patients who are younger than 18 years at the time of consent.\n\nExclusion Criteria (EC):\n\n* EC1. Meets any contraindication in the Vercise System locally applicable Directions for Use.","7 Years",{"count":520,"type":22},300,"To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.",[523],"Dystonia",{"date":304,"type":37},{"date":526,"type":37},"2016-03-07",{"date":453,"type":22},{"name":43,"class":44},36,{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":543,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":555},"100598303","safety-and-effectiveness-of-left-bundle-branch-area-pacing-versus-conventional-cardiac-resynchronization-therapy-in-heart-failure-100598303","NCT07069738","Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure","SYNCHRONICITY","Inclusion Criteria:\n\n1. Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law\n2. Patient meets a guideline-based indication for a de novo CRT-D device\n3. Primary prevention indication for ICD therapy\n4. Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)\n5. NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)\\* for at least 3 months\n\n   \\*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications\n6. Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment\n7. Patient is willing to participate in LATITUDE™ NXT remote patient monitoring\n8. Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)\n9. Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)\n\nExclusion Criteria:\n\n1. Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record\n2. Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and\u002For other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment\n3. Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment\n4. Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment\n5. Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)\n6. Prior or planned mechanical or bioprosthetic tricuspid valve replacement\n7. Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment\n8. Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment\n9. History of heart transplantation or left ventricular assist device (LVAD) implantation\n10. Less than 1 year of life expectancy at the time of enrollment\n11. Anticipated heart transplantation or LVAD implantation within 1 year of enrollment\n12. History of ventricular septal defect (VSD)\n13. Complex congenital heart disease\n14. Documented diagnosis of cardiac amyloidosis\n15. Known occlusion or other reason limiting central venous access for transvenous leads\n16. Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)\n17. Patient currently requiring dialysis\n18. Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)\n19. Patient with contrast dye allergy or unwilling\u002Fable to undergo pre-treatment with steroids and\u002For diphenhydramine\n20. Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome\n21. Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies\u002Fregistries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.",{"count":538,"type":22},850,[25],"This study will compare two different methods to pace the heart to treat heart failure including:\n\n1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).\n2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.",[542],"Heart Failure - NYHA II - IV",[544,329,545,546,547],"Heart Failure","Primary Prevention","Cardiac Resynchronization Therapy","Left Bundle Branch Area Pacing","2026-08-03",{"date":472,"type":37},{"date":551,"type":37},"2025-10-22",{"date":553,"type":22},"2029-11",{"name":43,"class":44},38,{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":563,"targetDuration":564,"studyType":163,"phases":4,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":105},"100558630","radiofrequency-rf-ablation-prospective-outcomes-study-for-central-nervous-system---rapid-for-cns-100558630","NCT06553625","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)\n* Signed a valid, IRB\u002FEC\u002FREB-approved informed consent form\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Directions for Use (DFU)\n* Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments",{"count":114,"type":22},"24 Months","The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.",[567,523,568,569],"Parkinson Disease","Essential Tremor","Movement Disorders",{"date":472,"type":37},{"date":572,"type":37},"2024-01-29",{"date":574,"type":22},"2035-12",{"name":43,"class":44},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":583,"targetDuration":317,"studyType":163,"phases":4,"briefSummary":584,"conditions":585,"keywords":586,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":593,"locationsCount":594},"100364994","boston-scientific-registry-of-deep-brain-stimulation-for-treatment-of-essential-tremor-et-100364994","NCT04032470","Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)","Boston Scientific Registry of Deep Brain Stimulations for Treatment of Essential Tremor (ET):ET Registry","Inclusion Criteria:\n\n* Meets criteria established in the locally applicable Directions for Use (DFU) for Essential Tremor\n* Is at least 18 years old\n\nExclusion Criteria:\n\n* Meets any contraindication in locally applicable Directions for Use",{"count":489,"type":22},"To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of Essential Tremor.",[568],[587,588,568],"Deep Brain Stimulation","Boston Scientific",{"date":472,"type":37},{"date":591,"type":37},"2019-10-23",{"date":508,"type":22},{"name":43,"class":44},20,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":608,"locationsCount":241},"100336760","deep-brain-stimulation-dbs-retrospective-outcomes-study-100336760","NCT03664609","Deep Brain Stimulation (DBS) Retrospective Outcomes Study","Inclusion Criteria:\n\n* Must be previously treated with or eligible for implantation with a deep brain stimulation system\n\nExclusion Criteria:\n\n* No Exclusion Criteria",{"count":161,"type":22},"The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.",[567,568,523],{"date":472,"type":37},{"date":606,"type":37},"2019-03-12",{"date":66,"type":22},{"name":43,"class":44},""]